Media coverage about Bristol-Myers Squibb (NYSE:BMY) has trended somewhat positive recently, according to Accern. Accern identifies positive and negative press coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Bristol-Myers Squibb earned a daily sentiment score of 0.22 on Accern’s scale. Accern also assigned media stories about the biopharmaceutical company an impact score of 46.2308476576107 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
These are some of the media stories that may have impacted Accern’s rankings:
- 3 Things In Biotech, May 19: Buy BMY? Oncolytics In Again? Atara’s Immunotherapy Data (seekingalpha.com)
- $0.86 EPS Expected for Bristol-Myers Squibb (BMY) This Quarter (americanbankingnews.com)
- Global Bipolar Disorder Market Growth Opportunities: Sumitomo Dainippon Pharma Co., Allergan, Bristol-Myers Squibb Company (marketwatch.com)
- Bristol-Myers Squibb (BMY) Highlights Breadth of Immuno-Oncology–Based Combination Research and Commitment to Advancing Precision Medicine at ASCO (streetinsider.com)
- Immunomedics Announces Positive Phase 2 Results (finance.yahoo.com)
Shares of Bristol-Myers Squibb traded down $0.03, reaching $52.71, during trading hours on Friday, according to Marketbeat.com. The stock had a trading volume of 6,440,125 shares, compared to its average volume of 9,642,854. The company has a debt-to-equity ratio of 0.45, a quick ratio of 1.39 and a current ratio of 1.52. The firm has a market capitalization of $86.16 billion, a price-to-earnings ratio of 17.51, a PEG ratio of 1.32 and a beta of 0.99. Bristol-Myers Squibb has a 52-week low of $49.96 and a 52-week high of $70.05.
Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings results on Thursday, April 26th. The biopharmaceutical company reported $0.94 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.85 by $0.09. The firm had revenue of $5.19 billion during the quarter, compared to analyst estimates of $5.25 billion. Bristol-Myers Squibb had a return on equity of 37.56% and a net margin of 4.37%. Bristol-Myers Squibb’s quarterly revenue was up 5.4% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.84 earnings per share. analysts forecast that Bristol-Myers Squibb will post 3.41 earnings per share for the current year.
The company also recently declared a quarterly dividend, which was paid on Tuesday, May 1st. Investors of record on Friday, April 6th were issued a $0.40 dividend. The ex-dividend date was Thursday, April 5th. This represents a $1.60 dividend on an annualized basis and a dividend yield of 3.04%. Bristol-Myers Squibb’s payout ratio is 53.16%.
BMY has been the subject of several recent analyst reports. Credit Suisse Group set a $58.00 target price on Bristol-Myers Squibb and gave the company a “hold” rating in a research report on Tuesday, April 17th. Argus restated a “buy” rating and set a $66.43 target price (down previously from $75.00) on shares of Bristol-Myers Squibb in a research report on Wednesday, March 21st. BMO Capital Markets dropped their target price on Bristol-Myers Squibb from $51.00 to $47.00 and set an “underperform” rating for the company in a research report on Wednesday, April 18th. JPMorgan Chase set a $75.00 target price on Bristol-Myers Squibb and gave the company an “overweight” rating in a research report on Tuesday, March 20th. Finally, Morgan Stanley upgraded Bristol-Myers Squibb from an “equal weight” rating to an “overweight” rating and boosted their target price for the company from $51.56 to $78.00 in a research report on Thursday, February 15th. Three investment analysts have rated the stock with a sell rating, twelve have assigned a hold rating and eight have given a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus target price of $63.68.
In other news, Director Dinesh C. Paliwal purchased 4,770 shares of the stock in a transaction that occurred on Monday, April 30th. The stock was purchased at an average price of $52.40 per share, for a total transaction of $249,948.00. Following the completion of the acquisition, the director now owns 8,027 shares of the company’s stock, valued at $420,614.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.23% of the stock is currently owned by insiders.
About Bristol-Myers Squibb
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers drugs in the various therapeutic classes, such as oncology; cardiovascular; immunoscience; and virology, including human immunodeficiency virus (HIV) infection.
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.